Rituximab 지연성과민반응에 대한 신속 탈감작 적용 1예
A case of rapid desensitization for rituximab-induced delayed hypersensitivity reaction
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Rituximab is a monoclonal antibody used for the treatment of B-cell malignancies, including diffuse large B-cell lymphoma. Infusion-related hypersensitivity reactions to rituximab is well known, and delayed hypersensitivity reactions to rituximab are also reported. Desensitization is commonly used to prevent immediate hypersensitivity reactions, but recently there have been cases of successful desensitization therapy for delayed hypersensitivity reactions. A 66-year-old patient who underwent rituximab treatment for diffuse large B-cell lymphoma showed repeated rituximab-induced delayed hypersensitivity reactions with whole body rashes. Intravenous rapid desensitization was performed by using a 1-bottle, 11-step protocol for 6 cycles and thereafter hypersensitivity reaction did not recur. We herein reported a case of delayed hypersensitivity reaction caused by rituximab, which was successfully desensitized using our 11-step protocol.
Abstract
Rituximab is a monoclonal antibody used for the treatment of B-cell malignancies, including diffuse large B-cell lymphoma. Infusion-related hypersensitivity reactions to rituximab is well known, and delayed hypersensitivity reactions to rituximab are also reported. Desensitization is commonly used to prevent immediate hypersensitivity reactions, but recently there have been cases of successful desensitization therapy for delayed hypersensitivity reactions. A 66-year-old patient who underwent rituximab treatment for diffuse large B-cell lymphoma showed repeated rituximab-induced delayed hypersensitivity reactions with whole body rashes. Intravenous rapid desensitization was performed by using a 1-bottle, 11-step protocol for 6 cycles and thereafter hypersensitivity reaction did not recur. We herein reported a case of delayed hypersensitivity reaction caused by rituximab, which was successfully desensitized using our 11-step protocol.
참고문헌 (13)
- 이은정, "Rituximab 주입관련 부작용발생 및 위험인자 분석", 한국임상약학회지, 23(3), pp.223~231 (2013), 한국임상약학회
- Jung JW, "The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital", Oncology, 86, pp.127~134 (2014)
- Wong JT, "Rituximab hypersensitivity: evaluation, desensitization, and potential mechanisms", J Allergy Clin Immunol Pract, 5, pp.1564~1571 (2017)
- 김시내, "미만성 거대 B세포 림프종 환자 치료 후 절대림프구수 감소율의 예후적 가치", 대한내과학회지, 76(1), pp.52~59 (2009), 대한내과학회
- Kimby E, "Tolerability and safety of rituximab (MabThera)", Cancer Treat Rev, 31, pp.456~473 (2005)
- 조영주, "약물 알레르기의 진단", 대한내과학회지, 76(3), pp.282~290 (2009), 대한내과학회
- Roselló S, "Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines", Ann Oncol, 28(suppl_4), pp.iv100~iv118 (2017)
- Yawalkar N, "Drug hypersensitivity", pp.242~250 (2007), Karger
- 윤도란, "Trimethoprim-sulfamethoxazole에 대해 지연성 과민반응을 보인 환자에서 성공적인 급속 탈감작 치료 사례 1예", Allergy Asthma & Respiratory Disease, 3(2), pp.155~158 (2015), 대한 소아알레르기 호흡기학회
- Posadas SJ, "Delayed drug hypersensitivity reactions - new concepts", Clin Exp Allergy, 37, pp.989~999 (2007)
- 허연정, "Fluconazole 지연형 과민반응에 대한 성공적인 탈감작 사례 1예", Allergy Asthma & Respiratory Disease, 6(1), pp.68~71 (2018), 대한 소아알레르기 호흡기학회[DOI]
- 이애라, "일차 항결핵제 모두에 과민반응을 보인 환자의 성공적 탈감작 결핵 치료 1예", Allergy Asthma & Respiratory Disease, 1(4), pp.395~399 (2013), 대한 소아알레르기 호흡기학회
- Teraki Y, "Successful desensitization to fixed drug eruption: the presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization", Dermatology, 209, pp.29~32 (2004)